Table 2. Characteristics and outcomes of pregnant women with confirmed drug-resistant tuberculosis (n = 6).

Maternal characteristics			Outcomes
TB presentation	TB treatment regimen	HIV features	Perinatal and infant 1	Maternal TB
• Pulmonary TB2 • M. tb (INH and RMP resistant) cultured from sputum within 13 d • 38 y, • Mixed race	• 3 m of OFX,ETO,PZA,EMB,TRD prior to delivery; • 9 m interruption post- delivery, and presented again with M.tb sputum (INH, RMP, ETH and OFX resistant)	• CD4 24 cells/mm3 • Previously diagnosed with HIV infection, 3 m prior to delivery (TDF, 3TC, NVP)	▪ Male, ▪ 1940 g, ▪ 38 w GA ▪ Alive at 9 m and completed 6 m of high dose INH, in place of safety. ▪ PCR HIV negative	Unfavourable
				(LTF)
▪ Pulmonary TB2     ▪ M. tb (INH and RMP resistant) cultured from sputum within 22 d     ▪ 28 y,     ▪ African	▪ 8 m of OFX, ETO, PZA,EMB,TRD and 5 m of TB treatment interruption prior to delivery. ▪ Mom was re-initiated on TB treatment post-delivery—adhered for 3 m, and then re-located	• CD4 410 cells/mm3 • Previously diagnosed with HIV infection, but defaulted ART 5 m prior to delivery PMTCT at delivery	▪ Male, ▪ 3100 g, ▪ 40 w GA ▪ Alive at 3 m and completed 3 m of high dose INH, then LTF. ▪ PCR HIV negative	Unfavourable
				(LTF)
• TB meningitis and miliary TB • M. tb (INH and RMP resistant) cultured from CSF within 18 d, • 29 y, • Mixed race	• 11 days of INH,RMP,PZA,EMB • M.tb culture results only became available after the mother had died	• CD4 87 cells/mm3 • Previously diagnosed with HIV infection, but defaulted ART 3 m prior to delivery	▪ Foetus died in utero	Unfavourable
				(died)
• Pulmonary TB 2 • M. tb (INH and RMP resistant) cultured from sputum within 22 d • 30 y, • African	• 18 m of OFX,ETO,PZA,EMB,TRD • 14 m prior to delivery, and 4 m post-delivery	• CD4 154 cells/mm3 • Previously diagnosed with HIV infection 14 m prior to delivery (ZDV, 3TC, EFV)	▪ Female, ▪ 2690 g, ▪ 40 w GA ▪ Alive at discharge from hospital. No TB medication indicated ▪ PCR HIV negative	Favourable
				(cured)
• Pulmonary TB • M. tb (INH and RMP resistant) cultured from sputum within 22 d • 38 y, • Mixed race	• 24 m of OFX,ETO,PZA,EMB,TRD • 9 m prior to delivery, and 15 m post-delivery	• HIV uninfected	▪ Male, ▪ 2920 g, ▪ 38 w GA ▪ Alive at discharged from hospital. ▪ No TB medication indicated	Favourable
				(cured)
Pulmonary TB • sM. tb (INH, RMP, ETH, OFX and AMK resistant) cultured from sputum within 24 d • 30 y, • African	• 1 m of OFX,ETO,PZA,EMB,TRD • Prior to delivery, followed by 8 m of extensively drug-resistant TB treatment 3	• HIV uninfected	▪ Female, ▪ 3625 g, ▪ 40 w GA ▪ Alive at 1 month and completed 1 month of high dose INH—then LTF (re-located with grandmother)	Unfavourable
				(LTF)

TB, tuberculosis; M. tb, Mycobacterium tuberculosis; INH, isoniazid; RMP, rifampicin; d, days; y, years; m, months; OFX, ofloxacin; ETO, ethionamide; PZA, pyrazinamide; EMB, ethambutol; TRD, terizidone; TDF, tenofovir; 3TC, lamivudine; NVP, nevirapine, g, grams; ZDV, zidovudine; EFV, efavirenz; w, weeks; GA, gestational age; ART, antiretroviral therapy; PCR, polymerase chain reaction; PMTCT, Prevention of mother-to-child-HIV transmission; CSF, cerebrospinal fluid

¹ No fetal abnormalities were detected at birth

² Previously treated for drug-susceptible TB

³ Mother was subsequently discharged from TB hospital and lost to follow-up